NCT00338728View on ClinicalTrials.gov

Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

October 3, 2003

Primary Completion Date

November 27, 2018

Study Completion Date

November 27, 2018

Conditions
Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor PositiveKIT PositivePDGFR PositivePostmenopausalProgesterone Receptor PositivePrognostic Stage IV Breast Cancer AJCC v8
Interventions
DRUG

Imatinib Mesylate

Given PO

DRUG

Letrozole

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00338728 - Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter